螞蟻消金獲股東增資及引入新股東 杭金數科持股10%為第二大股東
據內媒報道,阿里巴巴-SW(09988.HK)(BABA.US)關聯公司螞蟻集團擬與一眾股東對旗下螞蟻消費金融增資105億元人民幣(下同),交易完成後,螞蟻消金註冊資本增加至185億元。
增資方包括螞蟻集團、杭金數科、舜宇光學(02382.HK)、傳化智聯、博冠科技、魚躍醫療(002223.SZ)和農信集團七家公司。
5名新股東包括杭州國資杭金數科、舜宇光學、傳化智聯、博冠科技、重慶國資重慶農信集團,持股比例合共25.55%。當中,杭金數科出資18.5億元,持股10%,成為第2大股東。舜宇光學出資11.1億元,持股6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.